ACTIVE INGREDIENT: Risperidone
STRENGTH, PACK SIZE & GMS CODES:
0.5 mg Film-Coated Tablets x 20 ~ 44069
1 mg Film-Coated Tablets x 20 ~ 44064
1 mg Film-Coated Tablets x 60 ~ 44040
2 mg Film-Coated Tablets x 60 ~ 44025
3 mg Film-Coated Tablets x 60 ~ 44046
6 mg Film-Coated Tablets x 28 ~ 44002
1 mg/ml Oral Solution 100ml x 1~ 44036
Risperidone is indicated for the treatment of schizophrenia.
Risperidone is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.
Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.
Risperidone is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with sub average intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacological treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.